Cytokine Therapy: A Standard of Care for Metastatic Renal Cell Carcinoma?

Hutson, Thomas E.; Quinn, David I.

doi:10.3816/cgc.2005.n.030

Cited by 34 publications

(22 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collectively, our results show that even the extremely low dose of IL-2 we used combined with IFN-α achieved a clinical effect without inferiority to the results reported in previous studies. 12,13,20,21 Our results may be supported by the rationale proposed by Buzio et al, 10,11 that the antitumor effect of immunotherapy is maintained at a much lower dose of IL-2 than those previously used. The route of IL-2 administration is another important issue that affects its effi cacy and toxicity.…”

Section: Discussionsupporting

confidence: 72%

“…20 Although 5-FU has been used to enhance the limited effi cacy of cytokine treatment, one prospective randomized trial concerning the additive effi cacy of fl uorouracil failed to show a benefi t from the addition of 5-FU to combined IFN-α and IL-2 treatment. 21 Nevertheless, the highest response rates in metastatic RCC have been reported with a combination of IFN-α, IL-2, and 5-FU, in studies by Atzpodien and colleagues (LopezHanninen et al 12 ).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 98%

Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience

et al. 2008

View full text Add to dashboard Cite

show abstract

“…More recently, tumour histology and CAIX expression were combined in a new predictive model, where tissue specimens from patients with good pathological prognosis alone or intermediate pathological prognosis with high CAIX expression were found to include 96% of responders to IL-2 treatment [42]. A recent report also suggests that patients who lack the mammalian target of rapamycin (mTOR) pathway and, in particular, those who have increased expression of phosphorylated Akt, might not respond well to cytokine therapy [43].…”

Section: Targeting Patients With Potential To Respond To Cytokine Thementioning

confidence: 99%

Establishing the role of cytokine therapy in advanced renal cell carcinoma

Gore

Mulder

2008

BJU International

View full text Add to dashboard Cite

Tribute to Professor Pieter De Mulder, from Martin Gore Pieter and I were often pitted against each other in debates at international meetings on the role of cytokine therapy. The truth is that there was little disagreement between us, but we both thought such set pieces were a good way to highlight the issues surrounding the use of cytokines. He wanted our true joint view to be put on record, and the result is this article. Pieter himself suffered from kidney cancer for many years and he died in April as we were putting the finishing touches to this manuscript. Pieter was a remarkable man in so many ways. He was a physician of great compassion, immense intellect, utter integrity and unshakeable scientific rigor. These qualities meant that his perspective on many clinical controversies was in great demand internationally. The European oncology community has lost one of its giants and I, a dear friend. This manuscript is dedicated to the memory of Professor Pieter de Mulder.

show abstract

“…Options are summarized in Table 7 related to levels of evidence for different MSK categories in first-line and for the prior therapy failed subsequently. Generally, first-line patients should be offered sunitinib, which has activity across all three MSK categories, although there is strong data for the use of temsirolimus in poor-risk patients and potential for cure in a small fraction of patients with good-risk disease given high-dose interleukin-2 [Hutson and Quinn, 2005]. Patients might also be offered bevacizumab and interferon-a or potentially sorafenib if they have evidence of cardiac failure or other vascular risk factors [Telli et al 2008;Chu et al 2007].…”

Section: Therapeutic Advances In Medical Oncology 1 (3)mentioning

confidence: 99%

Review: Targeted therapy in renal cancer

2009

Self Cite

View full text Add to dashboard Cite

Renal cell cancer (RCC) has an increasing incidence internationally and is a disease for which there have been limited therapeutic options until recently. The last decade has seen a vastly improved understanding of the biological and clinical factors that predict the outcome of this disease. We now understand some of the different molecular underpinnings of renal clear cell carcinoma by mutation or silencing of the von Hippel Lindau (VHL) gene and subsequent deregulated proliferation and angiogenesis. Survival in advanced disease is predicted by factors (performance status, anemia, hypercalcemia, and serum lactate dehydrogenase, time from diagnosis to recurrence) incorporated into the Memorial Sloan Kettering Cancer Center (MSKCC) criteria (also referred to as 'Motzer' criteria). These criteria allow classification of patients with RCC into good, intermediate and poor risk categories with median overall survivals of 22 months, 12 months and 5.4 months, respectively. Predicated upon these advances, six new targeted drugs (sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab and pazopanib) have been tested in well-designed phase III trials, selected or stratified for MSKCC risk criteria, with positive results. All of these new drugs act at least in part through vascular endothelial growth factor (VEGF) mediated pathways with other potential therapeutic impact on platelet-derived growth factor (PDGF), raf kinase and mammalian target of rapamycin (mTOR) pathways. Importantly, data from each of these trials show a consistent doubling of progression-free survival (PFS) over prior standard of care treatments. In addition, sorafenib, sunitinib and temsirolimus, have demonstrated significant overall survival (OS) benefits as well; further follow-up is required to determine whether the disease control exhibited by everolimus and pazopanib will translate into a survival advantage. These drugs are generally well tolerated, as demonstrated by quality-of-life improvement in clinical trials, and result in clinical benefit for in excess of 70% of patients treated. They have challenged the traditional outcomes of clinical trial design by achieving their benefits with relatively few radiographic responses, but high rates of disease stability. The unique side-effect profile coupled with the chronicity of therapy requires increased vigilance to maximize exposure to the drugs while maintaining quality of life and minimizing toxicity. This review focuses on the background, clinical development and practical use of these new drugs in RCC.

show abstract

Cytokine Therapy: A Standard of Care for Metastatic Renal Cell Carcinoma?

Cited by 34 publications

References 49 publications

Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience

Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience

Establishing the role of cytokine therapy in advanced renal cell carcinoma

Review: Targeted therapy in renal cancer

Contact Info

Product

Resources

About